Expression of Cleaved SNAP-25 After Bladder Wall Injection of OnabotulinumtoxinA or AbobotulinumtoxinA: A Comparative Study in the Mice

被引:5
作者
Oliveira, Raquel [1 ,2 ,3 ]
Coelho, Ana [2 ,3 ,4 ]
Charrua, Ana [1 ,2 ,3 ,4 ]
Avelino, Antonio [2 ,3 ]
Cruz, Francisco [2 ,3 ,4 ,5 ]
机构
[1] Univ Porto, Fac Med, Dept Expt Biol, Oporto, Portugal
[2] Univ Porto, Inst Invest & Inovacao Saude, Oporto, Portugal
[3] Univ Porto, Inst Biol Mol & Celular, Oporto, Portugal
[4] Univ Porto, Fac Med, Dept Renal Urol & Infect Dis, Oporto, Portugal
[5] Hosp Sao Joao, Dept Urol, Oporto, Portugal
关键词
botulinum toxin type A; conversion ratio; cSNAP-25; relative potency; urinary bladder; NEUROGENIC DETRUSOR OVERACTIVITY; PLACEBO-CONTROLLED TRIAL; TOXIN TYPE-A; LOWER URINARY-TRACT; BOTULINUM-TOXIN; DOUBLE-BLIND; INCONTINENCE; DYSPORT; BOTOX; MANAGEMENT;
D O I
10.1002/nau.22900
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aims: To study the expression of cleaved synaptosomal associated protein of 25kDa (cSNAP-25) in the bladder wall injected with onabotulinumtoxinA(onabotA) or abobotulinumtoxinA(abobotA) and compare the relative potency of these two brands. Methods: One injection of 0.5 U of onabotA or abobotA diluted in 2 mu l of saline was carried out in the bladder dome of adult female mice, whose bladders were exposed by laparotomy. Three days later bladders were collected, divided in five segments (dome, upper, middle and lower body, and trigone) and each one was sectioned and immunoreacted against cSNAP-25, the end product of botulinum toxin type A (BoNT/A) activity. From each of the five segments one section was taken at random and the number of cSNAP-25 immunoreactive (IR) fibers was determined. Results: Each injection resulted in the cleavage of SNAP-25 in all bladder sections, including those of the more distant segment from the injection point. The average number of cSNAP-25 positive fibers was higher in the onabotA, 341 +/- 301, than in the abobotA-treated mice, 208 +/- 152 (P = 0.003). The number of cSNAP-25 IR fibers varied three to five-fold between animals of each experimental group. Conclusions: These findings confirm that, when injected in the bladder wall, in the same unit amount and same volume, onabotA is 1.6 timesmore potent to cleave SNAP-25 than abobotA. The conversion ratio suggested by these experiments is 1: 1.6 between onabotA and abobotA. Each injection, although preformed in the same way, may induce substantially different amounts of cSNAP-25. (C) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:86 / 90
页数:5
相关论文
共 22 条
  • [1] Rodent Models for Urodynamic Investigation
    Andersson, Karl-Erik
    Soler, Roberto
    Fuellhase, Claudius
    [J]. NEUROUROLOGY AND URODYNAMICS, 2011, 30 (05) : 636 - 646
  • [2] Long-distance retrograde effects of botulinum neurotoxin A
    Antonucci, Flavia
    Rossi, Chiara
    Gianfranceschi, Laura
    Rossetto, Ornella
    Caleo, Matteo
    [J]. JOURNAL OF NEUROSCIENCE, 2008, 28 (14) : 3689 - 3696
  • [3] Vanilloid receptor 1 expression in the rat urinary tract
    Avelino, A
    Cruz, C
    Nagy, I
    Cruz, F
    [J]. NEUROSCIENCE, 2002, 109 (04) : 787 - 798
  • [4] Minimal Effective Dose of Dysport and Botox in a Rat Model of Neurogenic Detrusor Overactivity
    Behr-Roussel, Delphine
    Oger, Stephanie
    Pignol, Bernadette
    Pham, Emmanuel
    Le Maux, Amelie
    Chabrier, Pierre-Etienne
    Caisey, Stephanie
    Compagnie, Sandrine
    Picaut, Philippe
    Bernabe, Jacques
    Alexandre, Laurent
    Giuliano, Francois
    Denys, Pierre
    [J]. EUROPEAN UROLOGY, 2012, 61 (05) : 1054 - 1061
  • [5] Botulinum toxin type A products are not interchangeable: a review of the evidence
    Brin, Mitchell F.
    James, Charmaine
    Maltman, John
    [J]. BIOLOGICS-TARGETS & THERAPY, 2014, 8 : 227 - 240
  • [6] OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial
    Chapple, Christopher
    Sievert, Karl-Dietrich
    MacDiarmid, Scott
    Khullar, Vik
    Radziszewski, Piotr
    Nardo, Christopher
    Thompson, Catherine
    Zhou, Jihao
    Haag-Molkenteller, Cornelia
    [J]. EUROPEAN UROLOGY, 2013, 64 (02) : 249 - 256
  • [7] Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments
    Chen, Sheng
    [J]. TOXINS, 2012, 4 (10) : 913 - 939
  • [8] Coelho A, 2012, EUR UROL, V61, P1186, DOI [10.1016/j.eururo.2012.03.009, 10.1016/j.eururo.2012.01.046]
  • [9] Distribution of the High-Affinity Binding Site and Intracellular Target of Botulinum Toxin Type A in the Human Bladder
    Coelho, Ana
    Dinis, Paolo
    Pinto, Rui
    Gorgal, Tiago
    Silva, Carlos
    Silva, Andre
    Silva, Joao
    Cruz, Celia D.
    Cruz, Francisco
    Avelino, Antonio
    [J]. EUROPEAN UROLOGY, 2010, 57 (05) : 884 - 890
  • [10] Chapter 5: Clinical Data in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)
    Cruz, Francisco
    Nitti, Victor
    [J]. NEUROUROLOGY AND URODYNAMICS, 2014, 33 : S26 - S31